J. Lin

发表

Indinavir analogues with blocked metabolism sites as HIV protease inhibitors with improved pharmacological profiles and high potency against PI-resistant viral strains.

Yuan Cheng, Jiunn H. Lin, W. Schleif, 2002, Bioorganic & medicinal chemistry letters.

Drug-drug interaction mediated by inhibition and induction of P-glycoprotein.

Jiunn H. Lin, J. Lin, 2003, Advanced drug delivery reviews.

Protein Binding as a Primary Determinant of the Clinical Pharmacokinetic Properties of Non-Steroidal Anti-Inflammatory Drugs

D. Cocchetto, D. E. Duggan, J. Lin, 1987, Clinical pharmacokinetics.

Inhibition and Induction of Cytochrome P450 and the Clinical Implications

A. Y. Lu, Jiunn H. Lin, J. Lin, 1998, Clinical pharmacokinetics.

A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase.

Mark Embrey, Samson M Jolly, Wei Xu, 2004, Proceedings of the National Academy of Sciences of the United States of America.

Complexities of glucuronidation affecting in vitro in vivo extrapolation.

B. Wong, J. Lin, 2002, Current drug metabolism.

Pharmacokinetics and Interactions of a Novel Antagonist of Chemokine Receptor 5 (CCR5) with Ritonavir in Rats and Monkeys: Role of CYP3A and P-Glycoprotein

T. Baillie, Sanjeev Kumar, P. Pearson, 2002, Journal of Pharmacology and Experimental Therapeutics.

Pharmacokinetic and Pharmacodynamic Properties of Histamine H2-Receptor Antagonists

J. Lin, J. Lin, 1991, Clinical pharmacokinetics.

Clinical Relevance of P-Glycoprotein in Drug Therapy

M. Yamazaki, J. Lin, 2003, Drug metabolism reviews.

Effect of Dexamethasone on the Intestinal First-Pass Metabolism of Indinavir in Rats: Evidence of Cytochrome P-450 A and p-Glycoprotein Induction

M. Yamazaki, M. Chiba, I. Chen, 1999 .

Dose‐dependent pharmacokinetics: Experimental observations and theoretical considerations

J. Lin, J. Lin, 1994, Biopharmaceutics & drug disposition.

Dose-Dependent Pharmacokinetics of MK-417, a Potent Carbonic Anhydrase Inhibitor, in Experimental Polycythemic and Anemic Rats

I. Chen, F. Deluna, J. Lin, 1991, Pharmaceutical Research.

A series of 5-(5,6)-dihydrouracil substituted 8-hydroxy-[1,6]naphthyridine-7-carboxylic acid 4-fluorobenzylamide inhibitors of HIV-1 integrase and viral replication in cells.

D. Hazuda, Jiunn H. Lin, W. Schleif, 2005, Bioorganic & medicinal chemistry letters.

β-Oxidation of Simvastatin in Mouse Liver Preparations

Thomayant Prueksaritanont, B. Ma, Jiunn H. Lin, 2001 .

Using real-time quantitative TaqMan RT-PCR to evaluate the role of dexamethasone in gene regulation of rat P-glycoproteins mdr1a/1b and cytochrome P450 3A1/2.

J. Hochman, Scott E. Fauty, T. Prueksaritanont, 2004, Journal of pharmaceutical sciences.

Role of P-Glycoprotein in Pharmacokinetics

Jiunn H. Lin, M. Yamazaki, J. Lin, 2003, Clinical pharmacokinetics.

HEPATIC UPTAKE OF THE NOVEL ANTIFUNGAL AGENT CASPOFUNGIN

Xin Xu, Wooin Lee, R. Kim, 2005, Drug Metabolism and Disposition.

Effects of fibrates on metabolism of statins in human hepatocytes.

R. Subramanian, T. Prueksaritanont, Y. Qiu, 2002, Drug metabolism and disposition: the biological fate of chemicals.

Interconversion Pharmacokinetics of Simvastatin and its Hydroxy Acid in Dogs: Effects of Gemfibrozil

T. Prueksaritanont, Y. Qiu, K. Michel, 2005, Pharmaceutical Research.

Evaluation of drug interactions with P-glycoprotein in drug discovery: in vitro assessment of the potential for drug-drug interactions with P-glycoprotein.

J. Hochman, T. Ohe, M. Yamazaki, 2002, Current drug metabolism.

Tissue distribution and pharmacodynamics: a complicated relationship.

Jiunn H. Lin, J. Lin, 2006, Current drug metabolism.

Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites.

Thomayant Prueksaritanont, T. Baillie, T. Prueksaritanont, 2006, Toxicology and applied pharmacology.

CYP Induction-Mediated Drug Interactions: in Vitro Assessment and Clinical Implications

Jiunn H. Lin, J. Lin, 2006, Pharmaceutical Research.

Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: an impact more than protein binding.

A. D. Rodrigues, Cuyue Tang, Yuh-Jing Lin, 2002, Drug metabolism and disposition: the biological fate of chemicals.

CSF as a surrogate for assessing CNS exposure: an industrial perspective.

Jiunn H. Lin, J. Lin, 2008, Current drug metabolism.

Challenges of Antibody Drug Conjugates in Cancer Therapy: Current Understanding of Mechanisms and Future Strategies

Jiunn H. Lin, Weirong Wang, Yue Guo, 2018, Current Pharmacology Reports.

Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus.

Jiunn H. Lin, W. Schleif, L. Gabryelski, 2005, Bioorganic & medicinal chemistry letters.

METABOLISM-BASED DRUG-DRUG INTERACTIONS: WHAT DETERMINES INDIVIDUAL VARIABILITY IN CYTOCHROME P450 INDUCTION?

A. Y. Lu, Cuyue Tang, J. Lin, 2005, Drug Metabolism and Disposition.

Synthesis and evaluation of pyridyl analogs of L-735,524: Potent HIV-1 protease inhibitors

P. Anderson, Jiunn H. Lin, P. Darke, 1994 .

Mechanistic studies on metabolic interactions between gemfibrozil and statins.

B. Ma, T. Baillie, P. Pearson, 2002, The Journal of pharmacology and experimental therapeutics.

Interactions of Human P-glycoprotein with Simvastatin, Simvastatin Acid, and Atorvastatin

Julia Qiu, Cuyue Tang, Thomayant Prueksaritanont, 2004, Pharmaceutical Research.

Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization.

B. Ma, T. Baillie, Jiunn H. Lin, 2002, Drug metabolism and disposition: the biological fate of chemicals.

Correlation betweenin vitro andin vivo drug metabolism rate: Oxidation of ethoxybenzamide in rat

Jiunn H. Lin, M. Hayashi, S. Awazu, 1978, Journal of Pharmacokinetics and Biopharmaceutics.

Chapter 30. Inhibition of Cytochrome P-450 and Implications in Drug Development

A. Y. Lu, J. Lin, 1997 .

An in-vitro cocktail assay for assessing compound-mediated inhibition of six major cytochrome P450 enzymes

Hai-zhi Bu, Jian-jun Guo, Jenny Zhan, 2014, Journal of pharmaceutical analysis.

A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivo.

R. Freidinger, Jiunn H. Lin, V. Garsky, 2002, Molecular cancer therapeutics.

Clinical Implications of CYP Induction-Mediated Drug–Drug Interactions

Jiunn H. Lin, Jian-jun Guo, J. Lin, 2012 .

Renal handling of biphosphonate alendronate in rats

Y. Sugiyama, Y. Kato, J. Lin, 1999, Biopharmaceutics & drug disposition.

Transporter-mediated drug interactions: clinical implications and in vitro assessment

Jiunn H. Lin, J. Lin, 2007, Expert opinion on drug metabolism & toxicology.

Cytochrome P450 in vitro reaction phenotyping: a re-evaluation of approaches used for P450 isoform identification.

A. Y. Lu, Regina W. Wang, J. Lin, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Assessing the Potential for Induction of Cytochrome P450 Enzymes and Predicting the In Vivo Response

Jiunn H. Lin, J. Lin, 2012 .

Role of Mechanistic Transport Studies in Lead Optimization

M. Bock, Jiunn H. Lin, J. Hochman, 2006 .

Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies.

Jiunn H Lin, J. Lin, 2009, Current drug metabolism.

A peptide–doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo

R. Freidinger, V. Garsky, P. Lumma, 2000, Nature Medicine.

Physiological pharmacokinetics of ethoxybenzamide based on biochemical data obtainedin vitro as well as on physiological data

Yuichi Sugiyama, Y. Sugiyama, Jiunn H. Lin, 1982, Journal of Pharmacokinetics and Biopharmaceutics.

Cycloalkylpiperazines as HIV-1 protease inhibitors: enhanced oral absorption

B. E. Evans, P. Anderson, Jiunn H. Lin, 1995 .

Substituted alkylpyridines as P3′ ligands for the hydroxyethylpiperazine class of HIV-1 protease inhibitors: Improved pharmacokinetic profiles

P. Anderson, P. Darke, W. Schleif, 1995 .

Thiophene derivatives as extremely high affinity P3′ ligands for the hydroxyethylpiperazine class of HIV-1 protease inhibitors

P. Anderson, P. Darke, W. Schleif, 1995 .

A new hydroxyethylamine class of HIV-1 protease inhibitors with high antiviral potency and oral bioavailability

P. Anderson, P. Darke, W. Schleif, 1994 .

In vitro andin vivo evaluation of the tissue-to-blood partition coefficient for physiological pharmacokinetic models

Yuichi Sugiyama, Y. Sugiyama, Jiunn H. Lin, 1982, Journal of Pharmacokinetics and Biopharmaceutics.

CYTOCHROME P 450 IN VITRO REACTION PHENOTYPING : A RE-EVALUATION OF APPROACHES USED FOR P 450 ISOFORM IDENTIFICATION

Regina W. Wang, LU ANTHONYY.H., J. Lin, 2003 .

Pharmacokinetic and pharmacodynamic variability: a daunting challenge in drug therapy.

Jiunn H Lin, J. Lin, 2007, Current drug metabolism.

Design and synthesis of highly potent HIV protease inhibitors with activity against resistant virus.

W. Schleif, L. Gabryelski, E. Emini, 2003, Bioorganic & medicinal chemistry letters.

Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains.

Jiunn H. Lin, L. Kuo, W. Schleif, 2002, Bioorganic & medicinal chemistry letters.

A combinatorial library of indinavir analogues and its in vitro and in vivo studies.

Yuan Cheng, Xin Xu, Lawrence C Kuo, 2002, Bioorganic & medicinal chemistry letters.

Applications and limitations of genetically modified mouse models in drug discovery and development.

Jiunn H. Lin, J. Lin, 2008, Current drug metabolism.

L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase

P. Anderson, W. Schleif, E. Emini, 1995, Antimicrobial agents and chemotherapy.

How significant is the role of P-glycoprotein in drug absorption and brain uptake?

Jiunn H Lin, J. Lin, 2004, Drugs of today.

Interindividual variability in inhibition and induction of cytochrome P450 enzymes.

A. Y. Lu, J. Lin, J. Lin, 2001, Annual review of pharmacology and toxicology.

J. Lin, J. Lin, 1995, Drug metabolism and disposition: the biological fate of chemicals.

Is the role of the small intestine in first-pass metabolism overemphasized?

T. Baillie, J. Lin, M. Chiba, 1999, Pharmacological reviews.

Role of pharmacokinetics and metabolism in drug discovery and development.

A. Y. Lu, J. Lin, A Y Lu, 1997, Pharmacological reviews.

Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine.

R. Miller, J. Lin, B. Arison, 1995, Drug metabolism and disposition: the biological fate of chemicals.

Uptake and Stereoselective Binding of the Enantiomers of MK-927, a Potent Carbonic Anhydrase Inhibitor, by Human Erythrocytes in Vitro

Jiunn H. Lin, Haiyung Cheng, Tsu-Han Lin, 1992, Pharmaceutical Research.

Prediction of Metabolic Drug Interactions: Quantitative or Qualitative?

P. Pearson, J. Lin, 2001 .

The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains.

Jiunn H. Lin, L. Kuo, W. Schleif, 2003, Bioorganic & medicinal chemistry letters.

Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.

E. A. O'neill, J. Vacca, B. Frantz, 1999, Journal of medicinal chemistry.

Pharmacokinetics and Interactions of a Novel CCR5 Receptor Antagonist with Ritonavir in Rats and Monkeys: Role of CYP3A and P-glycoprotein

T. Baillie, Jiunn H. Lin, Sanjeev Kumar, 2002 .

Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4.

J. Hochman, J. Lin, M. Yamazaki, 2000, The Journal of pharmacology and experimental therapeutics.

Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A.

B. Ma, J. Lin, T. Prueksaritanont, 2000, Drug metabolism and disposition: the biological fate of chemicals.

Metabolic activation of a pyrazinone-containing thrombin inhibitor. Evidence for novel biotransformation involving pyrazinone ring oxidation, rearrangement, and covalent binding to proteins.

T. Baillie, P. Pearson, B. Wong, 2003, Chemical research in toxicology.

Dose-Dependent Pharmacokinetics of L-693,612, a Carbonic Anhydrase Inhibitor, Following Oral Administration in Rats

B. Wong, P. J. Bruhin, J. Lin, 1994, Pharmaceutical Research.

Role of Lymphatic System in Subcutaneous Absorption of Therapeutic Proteins

Weirong Wang, J. Lin, 2015 .

In Vitro and in Vivo CYP3A64 Induction and Inhibition Studies in Rhesus Monkeys: A Preclinical Approach for CYP3A-Mediated Drug Interaction Studies

B. Carr, T. Prueksaritanont, Y. Qiu, 2006, Drug Metabolism and Disposition.

Role of pharmacokinetics in the discovery and development of indinavir.

Lin, J. Lin, 1999, Advanced drug delivery reviews.

Renal handling of biphosphonate alendronate in rats

Y. Sugiyama, Y. Kato, I. Kino, 1999, Biopharmaceutics & drug disposition.

Nonlinear pharmacokinetics of efavirenz (DMP-266), a potent HIV-1 reverse transcriptase inhibitor, in rats and monkeys.

J. Lin, F. Deluna, S. Balani, 1999, Drug metabolism and disposition: the biological fate of chemicals.